Results 111 to 120 of about 54,096 (328)
Australasian Journal of Dermatology, EarlyView.ABSTRACT Background Mucous membrane pemphigoid (MMP) has a broad range of clinical manifestations, from relatively benign self‐limiting oral lesions to significant scarring (cicatrizing) of the oral, nasal and ocular tissues with severe functional impairment and morbidity.
Bronte Jeffrey +9 more
wiley +1 more source
Perspective: Speculative role of Tmp21 mediated protein secretory pathway during endoplasmic reticulum (ER) stress induced chronic inflammation [PDF]
arXiv, 2016 By deploying myelofibrosis as the disease context, I wish to propose that increased availability of Tmp21 (an NFAT gene target) induces aberrant protein secretion from the ER contributing to pathological consequences, which has not been elucidated before.
arxiv
Cancer, 2019 After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may predict drug discontinuation in patients with ...
F. Palandri +35 more
semanticscholar +1 more source
JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients [PDF]
, 2015 Background : Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping phenotype.
Faradz, S. M. (Sultana) +2 more
core +3 more sources
Outcome of Transplantation for Myelofibrosis
Biology of Blood and Marrow Transplantation, 2010 Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and ...
Theresa Hahn +23 more
openaire +3 more sources
British Journal of Clinical Pharmacology, Volume 91, Issue 4, Page 1171-1181, April 2025.Aim To evaluate the effectiveness of a Bayesian adaptive dosing strategy in achieving target busulfan exposure in adult patients undergoing haematopoietic cell transplantation (HCT). Methods This study included 71 adult patients scheduled to receive high‐dose busulfan. Busulfan was administered to achieve a cumulative area under the curve (AUC) of 66.0
Dorian Protzenko +6 more
wiley +1 more source
Blood, 2019 Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scoring systems aim to select patients for transplantation.
N. Gagelmann +13 more
semanticscholar +1 more source
Haematologica, 2019 In this study we interrogated the DNA methylome of myelofibrosis patients using high-density DNA methylation arrays. We detected 35,215 differentially methylated CpG, corresponding to 10,253 genes, between myelofibrosis patients and healthy controls ...
Nicolás Martínez-Calle +15 more
doaj +1 more source
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
British Journal of Haematology, EarlyView.Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan +2 more
wiley +1 more source
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing [PDF]
, 2013 Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and ...
Jorge Cortes, Ruben A Mesa
core +1 more source